相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Amer M. Zeidan et al.
ANNALS OF HEMATOLOGY (2019)
Iron overload in myelodysplastic syndromes (MDS)
Norbert Gattermann
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
To chelate or not to chelate in MDS: That is the question!
Amer M. Zeidan et al.
BLOOD REVIEWS (2018)
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes
Antonis Kattamis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Shannon A. Wong et al.
LEUKEMIA RESEARCH (2018)
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
Jamile M. Shammo et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
Heather A. Leitch et al.
LEUKEMIA RESEARCH (2018)
Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM ) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles
Mohamed A. Yassin et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2018)
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study
Emanuele Angelucci et al.
BLOOD (2018)
Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies
Ivo Abrahama et al.
LEUKEMIA RESEARCH (2017)
Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies
Claudia Pileggi et al.
PLOS ONE (2017)
Deferasirox for managing iron overload in people with thalassaemia
Claudia Bollig et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A. Leitch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent β-thalassemia major
Hossein Karami et al.
CLINICS AND PRACTICE (2017)
Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients
Ana Cristina Goncalves et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
Nicole Carreau et al.
BLOOD REVIEWS (2016)
Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry
Anna Waszczuk-Gajda et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry
Saskia Langemeijer et al.
BLOOD (2016)
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata
Luca Maurillo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Amer M. Zeidan et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Angel F. Remacha et al.
ANNALS OF HEMATOLOGY (2015)
The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome
Arch G. Mainous et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
Emanuele Angelucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2014)
Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome
Yang Jo Chung et al.
LEUKEMIA RESEARCH (2014)
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge et al.
LEUKEMIA RESEARCH (2014)
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
F. Nolte et al.
ANNALS OF HEMATOLOGY (2013)
Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients
Wenyi Lu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mhairi Mitchell et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
Norbert Gattermann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Norbert Gattermann et al.
LEUKEMIA RESEARCH (2010)
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
Anastasios Raptis et al.
TRANSFUSION (2010)
The deleterious effects of iron overload in patients with myelodysplastic syndromes
Francois Dreyfus
BLOOD REVIEWS (2008)
Myelodysplasia and Good syndrome. A case report
M. Di Renzo et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2008)
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670):: a 1-yr prospective study
John Porter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome
Hussam Ghoti et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
